## **Supplementary Information**

# Specificity of end resection pathways for double-strand break regions containing ribonucleotides and base lesions

Daley et al.







Supplementary Figure 1: Effect of RNA on EXO1. a, yExo1 (10, 20, 30, 40 nM) was incubated with the indicated substrate (2.5 nM) at 37°C for 10 min as in Figure 1a. Products were resolved in a 20% denaturing polyacrylamide gel. b, EXO1 was incubated with the indicated substrate (2.5 nM) containing 5' overhangs on the unlabeled strand at 37°C for 10 min as in Figure 1a. c, EXO1 deletion mutants as indicated (2.5, 5, 7.5, 10 nM) were incubated with the indicated substrate (2.5 nM) at 37°C for 10 min as in a. d, Lambda exonuclease (NEB) (0.05, 0.1, 0.2, 03 U) was incubated with the indicated substrate (2.5 nM) at 37°C for 10 min as in a. Error bars in all the panels represent the standard deviation of results from n=3 independent experiments.



supplementary Figure 2: Effect of KNA of DNA2. a, BLM (25 of 50 hM) ATPase assay was performed in the presence of ssDNA or ssRNA, and ATP was separated from Pi on a TLC plate. b, Blown-up version of the same gel shown in **Figure 4a**. c, yDna2 (0.25, 0.5, 0.75 nM) was incubated with the indicated Y shaped substrate (2.5 nM) at 30°C for 5 min in the presence or absence of 2 mM ATP. Reaction mixtures were resolved in a 20% denaturing polyacrylamide gel. d, DNA2 (0.25, 0.5, 0.75 nM) was incubated with the indicated Y shaped substrate (2.5 nM) at 37°C for 5 min in the presence of 2 mM ATP, with or without RPA (10 nM). Error bars in all the panels represent the standard deviation of results from n=3 independent experiments.





**Supplementary Figure 3: Optimal RPA foci formation depends on both EXO1 and DNA2. a**, U2OS cells were depleted of EXO1 or DNA2 using siRNA as indicated, and knockdown verified by western blotting. Cells were screened for resection defects by quantifying IR-induced RPA foci 3hr after treatment with 6Gy IR. Representative images of mock-irradiated or irradiated (IR) cells immunostained with anti-RPA antibody (red) are shown. Nuclei were stained with 4',6-diamidi-no-2-phenylindole (blue). Average numbers of RPA foci per nucleus are plotted. All experiments were replicated three times. Error bars depict standard error of the mean and \*\*\*\* indicates p < 0.0001; two-tailed unpaired-t-test. The scale bar represents 10 µm for all images. **b**, U2OS cells were depleted of OGG1, EXO1 or DNA2 using siRNA as indicated, and knockdown verified by western blotting. **c**, U2OS cells were depleted of APE1, EXO1 or DNA2 using siRNA as indicated, and knockdown verified by western blotting. **d**, U2OS cells were depleted of RNase H2A, EXO1 or DNA2 using siRNA as indicated, and knockdown verified by western blotting. **d**, U2OS cells were depleted of RNase H2A, EXO1 or DNA2 using siRNA as indicated, and knockdown verified by western blotting. WCE, whole cell extract; NUC, nuclear extract.

## Figure 2a



Supplementary Figure 4: Uncropped gels. Black rectangles indicate cropping locations.

## siEXO1 ÷ -÷ siDNA2 250--150\_~ EXO1 100--250-~ 150-DNA2 100 50actin 37

**Supplementary Figure 3a** 

### siOGG1 ŧ ŧ ŧ . ŧ siEXO1 • • • • ŧ siDNA2 50-• OGG1 37— 25 50actin 37— 250— 150--EXO1 100-

**Supplementary Figure 3b** 

## **Supplementary Figure 3c**



### **Supplementary Figure 3d**



Supplementary Figure 5: Uncropped western blots. Black rectangles indicate cropping locations.

DNA2

actin

250-

150-

100-

50-

37. - **Supplementary Table 1:** Sequences of oligonucleotides used in this study. Ribonucleotides are indicated in red, and alternative bases are shown in bold between parenthesis.

Name	Sequence	Description
PSOL9816	GGACATCTTTGCCCACCTGGTGGTGGGACC	30 bp dsDNA substrate
PSOL9817	GGTCCCACCAGGTGGGCAAAGATGTCC	30 bp dsDNA substrate
PSOL10488	<b>G</b> GACATCTTTGCCCACCTGGTGGGGACC	1-nt 5' RNA version of PSOL9816
PSOL10208	GGACATCTTTGCCCACCTGGTGGGGACC	4-nt 5' RNA version of PSOL9816
PSOL11407	GGACAUCUUUGCCCACCTGGTGGGGACC	10-nt 5' RNA version of PSOL9816
PSOL9275	GTAAGTGCCGCGGTGCGGGGGCGCGCGCGCCCCT	Nick substrate (top left)
PSOL9276	TGGGCTCCCCGGGCGCGTACTCCACCTCATGCATC	Nick substrate (top right)
PSOL10489	UGGGCTCCCCGGGCGCGTACTCCACCTCATGCATC	4-nt 5' RNA version of PSOL9276
PSOL9022	GATGCATGAGGTGGAGTACGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCACCCGCACCGCGCACTTAC	Nick substrate (bottom)
PSOL9822	GGACAUCUUUGCCCACCUGGUGGGGGACC	RNA version of PSOL9816
PSOL9823	GGUCCCACCAGGUGGGCAAAGAUGUCC	RNA version of PSOL9817
PSOL11408	GGTCCCACCAGGTGGGCAAAGATGTCCGATCA	4-nt 3' tail version of PSOL9817
PSOL11708	GGACAUCUTTGCCCACCTGGTGGGGGACC	4-nt internal RNA version of PSOL9816
PSOL10547	GGTCCCACCACGUGGGCAAAGAUGUCC	15-nt 3' RNA version of PSOL9817
PSOL10545	GGTCCCACCAGGTGGGCAAAGATGTC <mark>C</mark>	1-nt 3' RNA version of PSOL9817
PSOL10546	GGTCCCACCAGGTGGGCAAAGAT <mark>GUCC</mark>	4-nt 3' RNA version of PSOL9817
PSOL10207	GGACATCTTT <mark>GCCC</mark> ACCTGGTGGGGACC	4-nt internal RNA version of PSOL9816
PSOL11408	GGTCCCACCAGGTGGGCAAAGATGTCCGATCA	5-nt 3' tail version of PSOL9817
PSOL11409	GGUCCCACCAGGUGGGCAAAGAUGUCCGAUCA	RNA version of PSOL11408
PSOL7343	AGAGGAAAGGAAGAAAGGAGGAAAGGACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC	Y substrate, top
PSOL7344	GCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCAGAATTCGGCAGGCTAGAAAGGAGGAAAGAAGGAAG	Y substrate, bottom
PSOL10490	AGAGGAAAGGAAGAAAGG <mark>AGGAA</mark> AGGACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC	4-nt internal RNA version of PSOL7343
PSOL10209	GGACATCTTT <b>(AP)</b> CCCACCTGGTGGTGGGACC	AP site version of PSOL9816
PSOL10210	GGACATCTTT <b>(8-0-G)</b> CCCACCTGGTGGTGGGACC	8-oxo-G site version of PSOL9816
PSOL10486	GGACATCTTTACCCACCTGGTGGGGACC	A-C mismatch version of PSOL9816
PSOL11779	AAGGTCCCACCAGGTGGGCAAAGATGTCC	2-nt 5' overhang version of PSOL9817
PSOL11711	AGAGGAAAGGAAGGAAGGAGGAAAGGACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC	4-nt 5' RNA version of PSOL7343

## Supplementary Table 2: siRNA sequences

Name	Sequence
OGG1	GAU CAA GUA UGG ACA CUG A
APE1	GCC UUU CGC AAG UUC CUG A
RNase H2A	GGA CUU GGA UAC UGA UUA U
EXO1	AG UGU UUC AGG AUC AAC AUC AUC
DNA2	UAC AAC AGC ACU CUU AUU CUG CUC C

Supplementary Table 3: Antibody sources and dilutions
---

Name	Vendor	Catalog No.	Western Blot Dilution	Immunofluorescence Dilution
OGG1	Abcam	ab124741	1:1000	
APE1	Santacruz	sc-17774	1:1000	
RNase H2A	Bethyl laboratory	A304-149A	1:1000	
EXO1	Bethyl laboratory	A302-639A	1:1000	
DNA2	Thermo	PA5-68167	1:1000	
Beta-actin	Cell signaling technology	122628	1:3000	
RPA	Millipore Sigma	MABE285		1:2000